ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

SNSS Sunesis Pharmaceuticals Inc

5.32
0.00 (0.00%)
After Hours
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Sunesis Pharmaceuticals Inc NASDAQ:SNSS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 5.32 4.72 4.75 0 01:00:00

Sunesis to Present at Upcoming Investor Conferences

14/05/2014 12:00pm

GlobeNewswire Inc.


Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart


From Aug 2019 to Aug 2024

Click Here for more Sunesis Pharmaceuticals Charts.

Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the company will present at two upcoming investor conferences.

Daniel Swisher, Chief Executive Officer of Sunesis, will present at the UBS Global Healthcare Conference on Tuesday, May 20, 2014 at 2:00 PM Eastern Time at The Sheraton New York Times Square Hotel in New York City.

Eric Bjerkholt, Executive Vice President, Corporate Development and Finance at Sunesis will present at the Jefferies 2014 Global Healthcare Conference on Tuesday, June 3, 2014 at 3:30 PM Eastern Time in New York City.

A live webcast of the presentations will be available on the Sunesis website at http://ir.sunesis.com. A replay of each webcast will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, Qinprezo™ (vosaroxin), in multiple indications to improve the lives of people with cancer. For additional information on Sunesis, please visit http://www.sunesis.com.

For additional information on Sunesis, please visit http://www.sunesis.com.

CONTACT: Investor and Media Inquiries:
         David Pitts
         Argot Partners
         212-600-1902
         
         Eric Bjerkholt
         Sunesis Pharmaceuticals Inc.
         650-266-3717
         
         Eliza Schleifstein
         Argot Partners
         917-763-8106
         eliza@argotpartners.com

1 Year Sunesis Pharmaceuticals Chart

1 Year Sunesis Pharmaceuticals Chart

1 Month Sunesis Pharmaceuticals Chart

1 Month Sunesis Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock